Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.55 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31379736 | 0.86 | ESR1 (0.53) | ESR1ESR2APPNPC1RAB9A | |
| SCHEMBL4050390 | 0.82 | ESR1 (0.53) | ESR1ESR2APPNPC1RAB9A | |
| SCHEMBL21231635 | 0.80 | LMNA (0.44) | ESR1ESR2NPC1RAB9ALMNA | |
| SCHEMBL10220833 | 0.80 | KDM4E (0.56) | NPC1RAB9ALMNA | |
| SCHEMBL2704182 | 0.80 | LMNA (0.44) | ESR1ESR2NPC1RAB9ALMNA | |
| SCHEMBL17087993 | 0.79 | LMNA (0.43) | ESR1ESR2LMNA | |
| SCHEMBL11929990 | 0.79 | PIK3CG (0.56) | RAB9ALMNA | |
| SCHEMBL2706715 | 0.78 | LMNA (0.56) | ESR1ESR2NPC1RAB9ALMNA | |
| SCHEMBL19749169 | 0.77 | LMNA (0.54) | ESR1ESR2NPC1RAB9ALMNA | |
| SCHEMBL23641698 | 0.76 | LMNA (0.41) | ESR1ESR2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162871-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2021-12-16 | — | — | US | disclosed |
| EP-3856176-A2 | INHIBITORS OF VAP-1 | Acucela Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164454-A | Inhibitors of VAP-1 | 奥克塞拉有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020069330-A2 | INHIBITORS OF VAP-1 | ACUCELA INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-1230227-B1 | BENZOXA-AND BENZOTHIAZOLYL SULFAMATES AND THEIR USE AS STEROID SULFATASE INHIBITORS | NOVARTIS AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| US-6716865-B1 | SUBSTITUTED AT THE 2 POSITION; A SULFAMATE BOUND VIA OXYGEN TO THE PHENYL PART OF THE RING STRUCTURE; SULFAMOYLATION; STEROID SULFATASE INHIBITOR, ACNE | NOVARTIS AG (CH) | 2004-04-06 | — | — | US | disclosed |
| US-4741994-A | PHENOL OR SULFONAMIDE COUPLER | FUJI PHOTO FILM CO., LTD. (JP) | 1988-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787791-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885APP 3512/4885 |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885APP 3512/4885 |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885APP 3512/4885 |
| US-12162871-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885APP 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.